Gut Microbes May Tilt the Odds in Cancer Immunotherapy
A Nature study in mice shows gut bacteria, particularly segmented filamentous bacteria, can enhance anti-PD-1 cancer immunotherapy via antigenic mimicry, implying the microbiome may influence treatment outcomes; human relevance remains unproven, but the finding fuels hope for microbiome‑based strategies to improve cancer therapies such as CAR T-cell approaches.